thrombopoietin receptor agonist (TPO-RA)

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, Peking Union Medical College Hospital

Conditions

Primary Evans Syndrome (ES)Primary Immune Thrombocytopenia (ITP)Severe Aplastic Anemia (SAA)Transfusion-dependent Non-severe Aplastic Anemia

Phase 2

A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

RecruitingNCT07421167

Novartis PharmaceuticalsPrimary Evans Syndrome (ES), Primary Immune Thrombocytopenia (ITP)

Start: 2026-11-11End: 2027-03-31Target: 164Updated: 2026-05-08

CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAA

Not yet recruitingNCT07558434

Peking Union Medical College HospitalSevere Aplastic Anemia (SAA), Transfusion-dependent Non-severe Aplastic Anemia

Start: 2026-04-01End: 2029-12-01Target: 43Updated: 2026-04-30